Background Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects of using oral contraceptives in…
Pregnant and lactating women are considered “therapeutic orphans” because they generally have been excluded from clinical drug research and the drug development process owing to legal, ethical, and safety concerns….
Obstetrical complications, often referred to as the “great obstetrical syndromes,” are among the most common global causes of mortality and morbidity in young women and their infants. However, treatments for…
Philippe Jeanty, MD, PhD, a pioneer in obstetric and gynecologic ultrasound, has made key contributions to the study of fetal anatomy, biometry, growth, and the diagnosis of congenital anomalies. He…
Obstetrical healthcare providers frequently field questions about the safety of medications recommended or prescribed to their pregnant patients. Most women use as least 1 medication during pregnancy; however, there is…
The data available to inform pregnant and lactating women about drug safety and efficacy are woefully inadequate. This lack of information encompasses every aspect of pharmaceutics, including limited human data…
